Related Content
T-DOT (Toronto Disparities, Overdose and Treatment), formerly OiSIS
T-DOT (Toronto Disparities, Overdose and Treatment) is an ongoing cohort study that started in 2018 (formerly OiSIS) of people who use drugs, looking at supervised consumption sites, drug checking, treatment, and the continuum of care. Sub-studies include: Injectable Opioid Agonist Treatment (iOAT) and Safer Opioid Supply (SOS or Prescribed Alternatives) program evaluations in Toronto.
View
Piloting and Evaluating Drug Checking Services in Toronto, Ontario
The pilot for Toronto’s Drug Checking Service, which checked and publicly reported on more than 10,000 samples between October 10, 2019, and June 30, 2023, was coordinated by the CDPE. While Toronto’s Drug Checking Service now operates from its own unit within MAP Centre for Urban Health Solutions at St. Michael’s Hospital, a site of Unity Health Toronto, the CDPE continues to work collaboratively with and conduct scientific research on the program.
View
Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
In March 2020, following a provincial COVID-19 emergency declaration, modifications to opioid agonist treatment (OAT) were introduced in Ontario, Canada to promote treatment access amid the pandemic and ongoing opioid overdose crisis. Our objectives were to evaluate the effects of these modifications on OAT enrollment and on receipt of take-home doses and the frequency of urine drug screening among OAT-enrolled participants, as well as to investigate concurrent pre- and post-implementation trends in opioid-related overdoses and all-cause mortality.
View
The Ontario Integrated Supervised Injection Services Cohort Study of People Who Inject Drugs in Toronto, Canada (OiSIS-Toronto): Cohort Profile
The Ontario Integrated Supervised Injection Services cohort in Toronto, Canada (OiSIS-Toronto) is an open prospective cohort of people who inject drugs established to evaluate the impacts of supervised consumption services integrated within three community health agencies on health status and service use.
View
Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications
We report the first detection of the psychoactive veterinary compound xylazine in Toronto, the largest urban center in Canada, by the city’s drug checking service.
View
Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic
The Ontario Drug Policy Research Network, the Office of the Chief Coroner for Ontario/the Ontario Forensic Pathology Service, Public Health Ontario, and the CDPE have published a report analyzing trends in opioid-related deaths and comparing circumstances of death between two groups: a COVID-19 pandemic cohort and a pre-pandemic cohort.
View